Spun out of SBIR firm Strategene Inc in 1994, Tera Biotechnology was structured around the developiment of massive libraries of cloned antibodies that contained many more antibodies than conventional screening techniques could access. The firm created its libraries using PCR to amplify antibody genes from a large collection of B-cells. With proprietary methods Tera Biotech could create and screen billions of antibodies, each of which can be biologically reproduced over and over, in a short amount of time. A very active SBIR player across several sources but whenthe system had been created, the cahllange was - what next. An important outcome of the success of Tera's work was the founding of new firm by Tera's principals focused on significantly curtailing cycle time for vaccine production. Called Favrille, the new firm the raised VC and went public (NASDAQ:FVRL) in 2005. The firm was subsequently acquired by MMR Global and ceased tradiing in 2009
